ProfoundBio US Co. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2018

Location

Seattle WA US

Primary Industry

Biotechnology

About

Founded in 2018 and based in Washington, US, ProfoundBio US Co., operates as a medical company for oncology biotherapeutics firms that are developing innovative antibody-based medicines with the potential to cure cancer patients. Mr. Baiteng Zhao is the Chairman and CEO of this company. It also has an office in Suzhou, China. In April 2024, Genmab A/S agreed to acquire ProfoundBio US Co. from Ally Bridge Group, T. Rowe Price, Janus Henderson Investors, RA Capital Management, OrbiMed Advisors, Surveyor Capital, Medicxi Ventures, Logos Capital, Octagon Capital, Piper Heartland Healthcare Capital, LifeSci Venture Partners,. Lilly Asia Ventures, LYFE Capital, K2VC, Chang'an Capital, and Gaorong Ventures for USD 1.8 billion. The company's product pipeline primarily consists of antibody-coupled drugs (ADCs) and other antibody-based therapeutic programs. In addition, it develops novel targeted drugs including PRO1184, an ADC drug targeting folate receptor alpha (FRα), and PRO1160, an ADC drug covering hematologic and solid tumor indications targeting CD70.

Current Investors

Chang'an Capital, Gaorong Ventures, K2VC

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment

Website

www.profoundbio.com/

Verticals

HealthTech

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.